SCHEMBL463192

SCHEMBL463192

CCOC(=O)/C(N)=N/Nc1cc(Cl)ccc1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.47
KDM4E B2RXH2 1/20 0.45
LMNA P02545 6/20 0.45
MAPK1 P28482 6/20 0.45
GAA P10253 4/20 0.45
ALDH1A1 P00352 2/20 0.45
TDP1 Q9NUW8 4/20 0.45
THRB P10828 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL463556 0.88 MAPT (0.52) MAPTL3MBTL1KMT2AMEN1KDM4E
SCHEMBL28338764 0.87 MAPT (0.51) MAPTL3MBTL1KMT2AMEN1KDM4E
SCHEMBL438297 0.84 MAPT (0.48) MAPTL3MBTL1KMT2AMEN1KDM4E
SCHEMBL463664 0.84 MAPT (0.47) MAPTL3MBTL1KMT2AMEN1KDM4E
SCHEMBL438411 0.82 ALDH1A1 (0.46) MAPTL3MBTL1KMT2AMEN1KDM4E
SCHEMBL438413 0.82 ALDH1A1 (0.46) MAPTL3MBTL1KMT2AMEN1KDM4E
SCHEMBL438412 0.82 ALDH1A1 (0.46) MAPTL3MBTL1KMT2AMEN1KDM4E
SCHEMBL9093727 0.80 L3MBTL1 (0.61) MAPTL3MBTL1KMT2AKDM4ELMNA
SCHEMBL34471139 0.80 MAPT (0.53) MAPTL3MBTL1KMT2AMEN1KDM4E
SCHEMBL442309 0.79 MAPT (0.47) MAPTL3MBTL1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
WO-2011112731-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed
WO-2010030785-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 MAPT 2336/4885L3MBTL1 3666/4885KMT2A 751/4885
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 MAPT 2336/4885L3MBTL1 3666/4885KMT2A 751/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 MAPT 2336/4885L3MBTL1 3666/4885KMT2A 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.